Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Baens M, Stirparo R, Lampi Y, Verbeke D, Vandepoel R, Cools J, Marynen P, de Bock CE, Bornschein S.

Eur J Immunol. 2018 Oct;48(10):1728-1738. doi: 10.1002/eji.201847597. Epub 2018 Aug 7.

2.

Small chromosomal regions position themselves autonomously according to their chromatin class.

van de Werken HJG, Haan JC, Feodorova Y, Bijos D, Weuts A, Theunis K, Holwerda SJB, Meuleman W, Pagie L, Thanisch K, Kumar P, Leonhardt H, Marynen P, van Steensel B, Voet T, de Laat W, Solovei I, Joffe B.

Genome Res. 2017 Jun;27(6):922-933. doi: 10.1101/gr.213751.116. Epub 2017 Mar 24.

3.

Identification of Intellectual Disability Genes in Female Patients with a Skewed X-Inactivation Pattern.

Fieremans N, Van Esch H, Holvoet M, Van Goethem G, Devriendt K, Rosello M, Mayo S, Martinez F, Jhangiani S, Muzny DM, Gibbs RA, Lupski JR, Vermeesch JR, Marynen P, Froyen G.

Hum Mutat. 2016 Aug;37(8):804-11. doi: 10.1002/humu.23012. Epub 2016 May 25.

4.

Nxf7 deficiency impairs social exploration and spatio-cognitive abilities as well as hippocampal synaptic plasticity in mice.

Callaerts-Vegh Z, Ahmed T, Vermaercke B, Marynen P, Balschun D, Froyen G, D'Hooge R.

Front Behav Neurosci. 2015 Jul 10;9:179. doi: 10.3389/fnbeh.2015.00179. eCollection 2015.

5.

MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.

Baens M, Bonsignore L, Somers R, Vanderheydt C, Weeks SD, Gunnarsson J, Nilsson E, Roth RG, Thome M, Marynen P.

PLoS One. 2014 Aug 8;9(8):e103774. doi: 10.1371/journal.pone.0103774. eCollection 2014.

6.

De novo MECP2 duplications in two females with intellectual disability and unfavorable complete skewed X-inactivation.

Fieremans N, Bauters M, Belet S, Verbeeck J, Jansen AC, Seneca S, Roelens F, De Baere E, Marynen P, Froyen G.

Hum Genet. 2014 Nov;133(11):1359-67. doi: 10.1007/s00439-014-1469-6. Epub 2014 Jul 19.

PMID:
25037250
7.

Evidence for increased SOX3 dosage as a risk factor for X-linked hypopituitarism and neural tube defects.

Bauters M, Frints SG, Van Esch H, Spruijt L, Baldewijns MM, de Die-Smulders CE, Fryns JP, Marynen P, Froyen G.

Am J Med Genet A. 2014 Aug;164A(8):1947-52. doi: 10.1002/ajmg.a.36580. Epub 2014 Apr 15.

PMID:
24737742
8.

Ubiquitin ligase HUWE1 regulates axon branching through the Wnt/β-catenin pathway in a Drosophila model for intellectual disability.

Vandewalle J, Langen M, Zschätzsch M, Nijhof B, Kramer JM, Brems H, Bauters M, Lauwers E, Srahna M, Marynen P, Verstreken P, Schenck A, Hassan BA, Froyen G.

PLoS One. 2013 Nov 26;8(11):e81791. doi: 10.1371/journal.pone.0081791. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/5a4ac42e-a148-4a89-b148-e47de0d72d16. Zschaetzsch, Marlen [corrected to Zschätzsch, Marlen].

9.

The mitochondrial solute carrier SLC25A5 at Xq24 is a novel candidate gene for non-syndromic intellectual disability.

Vandewalle J, Bauters M, Van Esch H, Belet S, Verbeeck J, Fieremans N, Holvoet M, Vento J, Spreiz A, Kotzot D, Haberlandt E, Rosenfeld J, Andrieux J, Delobel B, Dehouck MB, Devriendt K, Fryns JP, Marynen P, Goldstein A, Froyen G.

Hum Genet. 2013 Oct;132(10):1177-85. doi: 10.1007/s00439-013-1322-3. Epub 2013 Jun 20.

PMID:
23783460
10.

Generation and characterization of an Nxf7 knockout mouse to study NXF5 deficiency in a patient with intellectual disability.

Vanmarsenille L, Verbeeck J, Belet S, Roebroek AJ, Van de Putte T, Nevelsteen J, Callaerts-Vegh Z, D'Hooge R, Marynen P, Froyen G.

PLoS One. 2013 May 13;8(5):e64144. doi: 10.1371/journal.pone.0064144. Print 2013.

11.

Telomere length homeostasis and telomere position effect on a linear human artificial chromosome are dictated by the genetic background.

Weuts A, Voet T, Verbeeck J, Lambrechts N, Wirix E, Schoonjans L, Danloy S, Marynen P, Froyen G.

Nucleic Acids Res. 2012 Dec;40(22):11477-89. doi: 10.1093/nar/gks926. Epub 2012 Oct 11.

12.

Copy-number gains of HUWE1 due to replication- and recombination-based rearrangements.

Froyen G, Belet S, Martinez F, Santos-Rebouças CB, Declercq M, Verbeeck J, Donckers L, Berland S, Mayo S, Rosello M, Pimentel MM, Fintelman-Rodrigues N, Hovland R, Rodrigues dos Santos S, Raymond FL, Bose T, Corbett MA, Sheffield L, van Ravenswaaij-Arts CM, Dijkhuizen T, Coutton C, Satre V, Siu V, Marynen P.

Am J Hum Genet. 2012 Aug 10;91(2):252-64. doi: 10.1016/j.ajhg.2012.06.010. Epub 2012 Jul 26.

13.

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.

Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, De Paepe P, Verhoef G, Marynen P, Vandenberghe P, De Wolf-Peeters C, Cools J, Wlodarska I.

Blood. 2011 Apr 14;117(15):4056-64. doi: 10.1182/blood-2010-06-291310. Epub 2011 Feb 15.

14.

Allele-specific copy number analysis of tumors.

Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Børresen-Dale AL, Kristensen VN.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5. doi: 10.1073/pnas.1009843107. Epub 2010 Sep 13.

15.

Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.

Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schöffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M.

Cancer Res. 2010 Sep 15;70(18):7304-14. doi: 10.1158/0008-5472.CAN-10-1543. Epub 2010 Aug 4.

16.

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Van Roosbroeck K, Cools J, Dierickx D, Thomas J, Vandenberghe P, Stul M, Delabie J, De Wolf-Peeters C, Marynen P, Wlodarska I.

Haematologica. 2010 Mar;95(3):509-13. doi: 10.3324/haematol.2009.014761.

17.

Comparative expressed sequence hybridization studies of t(11;18)(q21;q21)-positive and -negative gastric MALT lymphomas reveal both unique and overlapping gene programs.

Sagaert X, Tousseyn T, Vanhentenrijk V, Van Loo P, Baens M, Marynen P, De Hertogh G, Geboes K, De Wolf-Peeters C.

Mod Pathol. 2010 Mar;23(3):458-69. doi: 10.1038/modpathol.2009.182. Epub 2010 Jan 15.

18.

Dosage-dependent severity of the phenotype in patients with mental retardation due to a recurrent copy-number gain at Xq28 mediated by an unusual recombination.

Vandewalle J, Van Esch H, Govaerts K, Verbeeck J, Zweier C, Madrigal I, Mila M, Pijkels E, Fernandez I, Kohlhase J, Spaich C, Rauch A, Fryns JP, Marynen P, Froyen G.

Am J Hum Genet. 2009 Dec;85(6):809-22. doi: 10.1016/j.ajhg.2009.10.019.

19.

Novel PORCN mutations in focal dermal hypoplasia.

Froyen G, Govaerts K, Van Esch H, Verbeeck J, Tuomi ML, Heikkilä H, Torniainen S, Devriendt K, Fryns JP, Marynen P, Järvelä I, Ala-Mello S.

Clin Genet. 2009 Dec;76(6):535-43. doi: 10.1111/j.1399-0004.2009.01248.x. Epub 2009 Oct 23.

PMID:
19863546
20.

T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response.

Van Loo P, Tousseyn T, Vanhentenrijk V, Dierickx D, Malecka A, Vanden Bempt I, Verhoef G, Delabie J, Marynen P, Matthys P, De Wolf-Peeters C.

Haematologica. 2010 Mar;95(3):440-8. doi: 10.3324/haematol.2009.009647. Epub 2009 Oct 1.

21.

Computational methods for the detection of cis-regulatory modules.

Van Loo P, Marynen P.

Brief Bioinform. 2009 Sep;10(5):509-24. doi: 10.1093/bib/bbp025. Epub 2009 Jun 4. Review.

PMID:
19498042
22.

A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.

Düwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D.

J Immunol. 2009 Jun 15;182(12):7718-28. doi: 10.4049/jimmunol.0803313.

23.

Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.

Noels H, Somers R, Liu H, Ye H, Du MQ, De Wolf-Peeters C, Marynen P, Baens M.

PLoS One. 2009;4(3):e4822. doi: 10.1371/journal.pone.0004822. Epub 2009 Mar 12.

24.

The atonal proneural transcription factor links differentiation and tumor formation in Drosophila.

Bossuyt W, De Geest N, Aerts S, Leenaerts I, Marynen P, Hassan BA.

PLoS Biol. 2009 Feb 24;7(2):e40. doi: 10.1371/journal.pbio.1000040.

25.

Atonal homolog 1 is a tumor suppressor gene.

Bossuyt W, Kazanjian A, De Geest N, Van Kelst S, De Hertogh G, Geboes K, Boivin GP, Luciani J, Fuks F, Chuah M, VandenDriessche T, Marynen P, Cools J, Shroyer NF, Hassan BA.

PLoS Biol. 2009 Feb 24;7(2):e39. doi: 10.1371/journal.pbio.1000039.

26.

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.

Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, Vandenberghe P.

Leukemia. 2009 May;23(5):845-51. doi: 10.1038/leu.2009.2. Epub 2009 Feb 12.

PMID:
19212337
27.

Evidence for co-evolution between human microRNAs and Alu-repeats.

Lehnert S, Van Loo P, Thilakarathne PJ, Marynen P, Verbeke G, Schuit FC.

PLoS One. 2009;4(2):e4456. doi: 10.1371/journal.pone.0004456. Epub 2009 Feb 11.

28.

Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation.

Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, Lippert E, Talmant P, Lafage-Pochitaloff M, Leroux D, Gervais C, Viguié F, Lai JL, Terre C, Beverlo B, Sambani C, Hagemeijer A, Marynen P, Delsol G, Dastugue N, Mecucci C, Brousset P.

J Exp Med. 2008 Oct 27;205(11):2499-506. doi: 10.1084/jem.20080285. Epub 2008 Oct 20.

29.

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, Wozniak A, Schöffski P, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2008 Sep 15;14(18):5749-58. doi: 10.1158/1078-0432.CCR-08-0533.

30.

Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.

De Keersmaecker K, Rocnik JL, Bernad R, Lee BH, Leeman D, Gielen O, Verachtert H, Folens C, Munck S, Marynen P, Fornerod M, Gilliland DG, Cools J.

Mol Cell. 2008 Jul 11;31(1):134-42. doi: 10.1016/j.molcel.2008.05.005.

31.

MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression.

Frints SG, Lenzner S, Bauters M, Jensen LR, Van Esch H, des Portes V, Moog U, Macville MV, van Roozendaal K, Schrander-Stumpel CT, Tzschach A, Marynen P, Fryns JP, Hamel B, van Bokhoven H, Chelly J, Beldjord C, Turner G, Gecz J, Moraine C, Raynaud M, Ropers HH, Froyen G, Kuss AW.

Eur J Hum Genet. 2008 Sep;16(9):1029-37. doi: 10.1038/ejhg.2008.66. Epub 2008 Apr 9.

32.

ModuleMiner - improved computational detection of cis-regulatory modules: are there different modes of gene regulation in embryonic development and adult tissues?

Van Loo P, Aerts S, Thienpont B, De Moor B, Moreau Y, Marynen P.

Genome Biol. 2008 Apr 7;9(4):R66. doi: 10.1186/gb-2008-9-4-r66.

33.

Nonrecurrent MECP2 duplications mediated by genomic architecture-driven DNA breaks and break-induced replication repair.

Bauters M, Van Esch H, Friez MJ, Boespflug-Tanguy O, Zenker M, Vianna-Morgante AM, Rosenberg C, Ignatius J, Raynaud M, Hollanders K, Govaerts K, Vandenreijt K, Niel F, Blanc P, Stevenson RE, Fryns JP, Marynen P, Schwartz CE, Froyen G.

Genome Res. 2008 Jun;18(6):847-58. doi: 10.1101/gr.075903.107. Epub 2008 Apr 2.

34.

In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J.

Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.

35.

Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation.

Froyen G, Corbett M, Vandewalle J, Jarvela I, Lawrence O, Meldrum C, Bauters M, Govaerts K, Vandeleur L, Van Esch H, Chelly J, Sanlaville D, van Bokhoven H, Ropers HH, Laumonnier F, Ranieri E, Schwartz CE, Abidi F, Tarpey PS, Futreal PA, Whibley A, Raymond FL, Stratton MR, Fryns JP, Scott R, Peippo M, Sipponen M, Partington M, Mowat D, Field M, Hackett A, Marynen P, Turner G, Gécz J.

Am J Hum Genet. 2008 Feb;82(2):432-43. doi: 10.1016/j.ajhg.2007.11.002. Epub 2008 Jan 24.

36.

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.

Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R.

Nat Immunol. 2008 Mar;9(3):263-71. doi: 10.1038/ni1561. Epub 2008 Jan 27.

PMID:
18223652
37.

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.

Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC, Maric I, Noel P, Kocabas C, Marynen P, Lessin LS, Wlodarska I, Robyn J, Metcalfe DD.

Haematologica. 2008 Jan;93(1):49-56. doi: 10.3324/haematol.11836.

38.

Detection and validation of copy number variation in X-linked mental retardation.

Bauters M, Weuts A, Vandewalle J, Nevelsteen J, Marynen P, Van Esch H, Froyen G.

Cytogenet Genome Res. 2008;123(1-4):44-53. doi: 10.1159/000184691. Epub 2009 Mar 11. Review.

PMID:
19287138
39.

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.

Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E.

Nat Genet. 2007 Sep;39(9):1120-6. Epub 2007 Aug 19.

PMID:
17704776
40.

Role of cardiac myocyte tissue factor in heart hemostasis.

Pawlinski R, Tencati M, Holscher T, Pedersen B, Voet T, Tilley RE, Marynen P, Mackman N.

J Thromb Haemost. 2007 Aug;5(8):1693-700.

41.

Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia.

Crescenzi B, La Starza R, Nozzoli C, Ciolli S, Matteucci C, Romoli S, Rigacci L, Gorello P, Bosi A, Martelli MF, Marynen P, Mecucci C.

Cancer Genet Cytogenet. 2007 Jul 1;176(1):67-71.

PMID:
17574967
42.

Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of XLMR genes.

Froyen G, Van Esch H, Bauters M, Hollanders K, Frints SG, Vermeesch JR, Devriendt K, Fryns JP, Marynen P.

Hum Mutat. 2007 Oct;28(10):1034-42.

PMID:
17546640
43.

Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL.

Pospisilova H, Baens M, Michaux L, Stul M, Van Hummelen P, Van Loo P, Vermeesch J, Jarosova M, Zemanova Z, Michalova K, Van den Berghe I, Alexander HD, Hagemeijer A, Vandenberghe P, Cools J, De Wolf-Peeters C, Marynen P, Wlodarska I.

Leukemia. 2007 Sep;21(9):2079-83. Epub 2007 May 24. No abstract available.

PMID:
17525729
44.

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink JP, Cools J.

Nat Genet. 2007 May;39(5):593-5. Epub 2007 Apr 15.

PMID:
17435759
45.

Loss of SLC38A5 and FTSJ1 at Xp11.23 in three brothers with non-syndromic mental retardation due to a microdeletion in an unstable genomic region.

Froyen G, Bauters M, Boyle J, Van Esch H, Govaerts K, van Bokhoven H, Ropers HH, Moraine C, Chelly J, Fryns JP, Marynen P, Gecz J, Turner G.

Hum Genet. 2007 Jun;121(5):539-47. Epub 2007 Feb 28.

PMID:
17333282
46.

A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome.

La Starza R, Rosati R, Roti G, Gorello P, Bardi A, Crescenzi B, Pierini V, Calabrese O, Baens M, Folens C, Cools J, Marynen P, Martelli MF, Mecucci C, Cuneo A.

Leukemia. 2007 Apr;21(4):830-3. Epub 2007 Feb 15. No abstract available.

PMID:
17301821
47.

A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.

Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P, Baens M.

J Biol Chem. 2007 Apr 6;282(14):10180-9. Epub 2007 Feb 7.

48.

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J.

Haematologica. 2007 Jan;92(1):27-34.

49.

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.

Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Gallì A, Specchia G, Martelli MF, Vandenberghe P, Cools J, Jones AV, Cross NC, Marynen P, Mecucci C.

Leukemia. 2007 Mar;21(3):397-402. Epub 2007 Jan 11.

PMID:
17215855
50.

The dark side of EGFP: defective polyubiquitination.

Baens M, Noels H, Broeckx V, Hagens S, Fevery S, Billiau AD, Vankelecom H, Marynen P.

PLoS One. 2006 Dec 20;1:e54.

Supplemental Content

Loading ...
Support Center